Ghana has been selected as one of eight countries globally to pilot a new World Health Organization (WHO) benchmarking tool. This tool assesses and strengthens institutional capacity for conducting high-quality clinical trials. The National Vaccine Institute (NVI) leads the pilot in Ghana, aiming to identify strengths and capacity gaps in clinical research systems.
The initiative focuses on supporting ethical, efficient, and scientifically rigorous clinical research. The WHO tool moves beyond simply counting trials. It provides a structured framework to evaluate systems and capabilities supporting clinical trials. This framework examines seven key areas, including patient engagement, scientific design, and regulatory oversight. It includes 32 functional objectives and 112 specific outcomes for assessment.
This pilot fits into Ghana's broader economic and political strategy to enhance its health and scientific infrastructure. The nation seeks to expand its capacity for research and vaccine manufacturing. Strengthening clinical trial systems is crucial for attracting investments and developing local pharmaceutical industries. This move aligns with Ghana's ambition to become a hub for medical innovation in West Africa, reducing reliance on external health solutions.
Dr. Sodzi Sodzi-Tettey, CEO of the NVI, stated the work connects to Ghana's long-term goals in vaccine development and manufacturing. He noted, “We are starting with fill-and-finish as a practical entry point, with the long-term goal of full end-to-end manufacturing.” This highlights the strategic importance of robust clinical trial systems for the entire vaccine production pipeline. Deputy Minister of Health, Dr. Grace Ayensu-Danquah, emphasised that building institutional systems is vital for achieving greater health sovereignty. She explained that research conducted outside Africa may not always address the specific needs of African populations.
The pilot involved a training workshop in Ho, Volta Region, for institutional teams. This prepared them for self-assessments using the new tool. A comprehensive assessment exercise followed from August 10 to 13, 2026. This involved 13 Ghanaian institutions, including the Noguchi Memorial Institute for Medical Research and the University of Ghana Medical Centre. Other participants included Revna Bioscience, the University of Cape Coast, and the Kintampo Health Research Centre. The NVI clarified that the exercise aims to support capacity development, not to rank institutions. It seeks continuous improvement across Ghana's clinical research ecosystem.
The findings from these 13 institutions will help identify common capacity gaps. These insights will guide future investments and national priorities in health research. As one of eight countries in the global pilot, Ghana will also contribute to refining the WHO's benchmarking tool. This participation could strengthen Ghana's position as a leading destination for clinical research in Africa and beyond. Improved clinical trial capabilities can attract foreign direct investment into the health sector. It can also create high-skilled jobs and foster local innovation, contributing significantly to economic growth.
WHO Technical Officer for Integrated Service Delivery, Dr. Angela Ackon, affirmed the value of the exercise. She stated, “This benchmarking exercise gives Ghanaian institutions a structured, evidence-based way to understand their own capabilities and chart a clear path for improvement.” This structured approach ensures that improvements are targeted and effective. The initiative also promotes regional cooperation, with African countries potentially developing specialised capabilities and working together as centres of excellence. This collaborative model can enhance the continent's overall health security and economic resilience.